FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy - STAT

The Food and Drug Administration rejected a marketing application from Capricor Therapeutics for a cell therapy to treat Duchenne muscular dystrophy, the company said Friday.  In its letter to Capri…